Navigation Links
United Therapeutics Reports Third Quarter 2007 Financial Results
Date:11/1/2007

including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Reform Act of 1995 for forward-looking statements. We are providing this information as of November 1, 2007, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. [uthr-g]

Remodulin and HeartBar are registered trademarks of United Therapeutics Corporation.

Beraprost is a trademark of Toray Industries, Inc.

OvaRex is a registered trademark of AltaRex Medical Corp.

UNITED THERAPEUTICS CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

(Unaudited) (Unaudited)

Revenues:

Net product sales $56,661 $38,931 $144,449 $109,301

Service sales 1,718 1,466 5,263 4,505

Distributor fees 666 - 1,333 -

Total revenues $59,045 40,937 151,045 113,806

Operating expenses:

Research and development 19,559 11,919 54,629 39,233

Research and development

expense related

to issuance of stock - - 11,013 -

Selling, general

and administrative 19,163 12,891 54,801 34,841

Impairment of

HeartBar tradename - - - 2,024

Cost of produc
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Inacom Education earns Wisconsin membership in United Training
2. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) ... commercializes proprietary technologies and products for advanced microarray diagnostics, ... for trading in the United States ... to commence on September 17, 2014 on the OTCQX ... trade on the TSX Venture Exchange under its existing ...
(Date:9/17/2014)... MARLBOROUGH, Mass. , Sept. 17, 2014 /PRNewswire/ ... ), a biotechnology company focused on discovering, developing ... needs using RNA-targeted technologies, today announced that it has ... Patent and Trademark Office on its unique delivery ... ® ) to phagocytic cells for the treatment ...
(Date:9/17/2014)... September 17, 2014 Beckman Coulter ... science and healthcare, has renewed its agreement with ... part of the agreement, Personify will continue to streamline ... emphasis on recruitment analytics, including time-to-fill, time-to-source and a ... our agreement with Personify was based on the success ...
(Date:9/17/2014)... 17, 2014 First ... from a truly novel class of anti-infective ... Biopharma, a biopharmaceutical company developing a truly ... it has secured £4.0m ($6.4m) to advance ... against a range of Gram-positive infections including  ...
Breaking Biology Technology:SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
...  Rhythm announced today that Lex Van der Ploeg, PhD, ... Van der Ploeg brings to Rhythm more than 25 ... and other therapeutic areas. "Lex has considerable ... pathways we are targeting with our ghrelin and melanocortin ...
... for Nanotechnology (LCN) have discovered electronic stripes, called ,charge ... that make up a graphitic superconductor. This is the ... and the finding is likely to have profound implications ... scientists believe will play a key role in the ...
... /PRNewswire-iReach/ --  Quantum Leap Innovations announced today the ... Directors.  Michael Cusumano is the Sloan Management Review Distinguished ... Sloan School of Management, with a joint appointment in ... STAYING POWER , covers six enduring principles for ...
Cached Biology Technology:Rhythm Names Lex Van der Ploeg Chief Scientific Officer 2Graphene earns its stripes 2Michael Cusumano, MIT's Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors 2Michael Cusumano, MIT's Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors 3Michael Cusumano, MIT's Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors 4
(Date:9/16/2014)... to Spain culminating the around the world of the ... how the global ocean works and what is its ... atmosphere is not limited to coastal areas, but also ... and it is already affecting the ocean ecosystem. ,This ... Residence for Researchers in Barcelona, in a congress that ...
(Date:9/16/2014)... 16, 2014 Schizophrenia is associated with increased rates ... of research suggests that the relationship between schizophrenia and ... to use nicotine to self-medicate symptoms and cognitive impairment ... in the current issue of Biological Psychiatry , ... the level of nicotine receptors in the brain was ...
(Date:9/16/2014)... choices such as buying clothing not made in a ... bringing their own bags when they go shopping? According ... Consumer Research , ethical consumption is motivated by a ... practices into action. , "Advocates of ethical consumerism suggest ... of the products they choose, but unfortunately only a ...
Breaking Biology News(10 mins):The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3Smoking and schizophrenia linked by alterations in brain nicotine signals 2Why are consumers willing to spend more money on ethical products? 2
... Research Hospital investigators have identified a novel structure in cells ... for eliminating damaged cells and also offers new therapeutic potential. ... work as cells ramp up production of p53 protein following ... how cells respond to the stress that damages DNA. The ...
... is available in Spanish . , A ... cooperators provides new details about how fertilizing soils with ... other cleaning suppliesinto the environment. Farmers add "Class ... their fields as a fertilizer. These biosolids meet federal ...
... Friday, Sept. 9, 2010 -- Keynote speakers have ... set for Dec. 5-8 at the Hilton in the ... conference theme is "Where Discovery Meets Innovation." The ... America conference will cover a wide range of topics ...
Cached Biology News:New insights provide promise for development of tools to protect damaged tissues 2New insights provide promise for development of tools to protect damaged tissues 3Tracking triclosan's field footprint 2
Request Info...
Imject Freund's Complete Adjuvant (FCA)...
... cytoplasmic granules, is a key step ... (e.g. basophils, neutrophils, eosinophils, and mast ... secretory granules contain many proinflammatory mediators ... proteases (Hallgren, 2001). Tryptase, a tetrameric ...
... Safe DNA gel stain was developed specifically for ... bromide for staining DNA in agarose or acrylamide ... mutagenic than ethidium bromide but SYBR Safe stain's ... bromide. SYBR Safe stain comes as a premixed ...
Biology Products: